X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS

期刊標題檢索 CRIT REV THER D 最新評論: The discussion section is the core part of an SCI paper because it ca... (2021-12-30)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS]您好,您是該頁面的第 12197 位訪客。

期刊簡介
期刊名稱CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
LetPub Score
6.1
50 ratings
Rate

Reputation
7.6

Influence
4.8

Speed
7.0

期刊簡稱CRIT REV THER DRUG
ISSN0743-4863
E-ISSN2162-660X
h-index69
CiteScore
CiteScoreSJRSNIPCiteScore Rank
5.500.5360.526
Subject fieldQuartilesRankPercentile
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmaceutical Science
Q263 / 183
Category: Pharmacology, Toxicology and Pharmaceutics
Subcategory: Pharmacology
Q2137 / 313

自引率 (2023-2024)13.30%自引率趨勢
掲載範囲
Therapeutic uses of a variety of drug carrier systems have significant impact on the treatment and potential cure of many chronic diseases, including cancer, diabetes mellitus, psoriasis, parkinsons, Alzheimer, rheumatoid arthritis, HIV infection, infectious diseases, asthma, and drug addiction. Scientific efforts in these areas are multidisciplinary, involving the physical, biological, medical, pharmaceutical, biological materials, and engineering fields.
Articles concerning this field appear in a wide variety of journals. With the vast increase in the number of articles and the tendency to fragment science, it becomes increasingly difficult to keep abreast of the literature and to sort out and evaluate the importance and reliability of the data, especially when proprietary considerations are involved. Abstracts and noncritical articles often do not provide a sufficiently reliable basis for proper assessment of a given field without the additional perusal of the original literature. This journal bridges this gap by publishing authoritative, objective, comprehensive multidisciplinary critical review papers with emphasis on formulation and delivery systems. Both invited and contributed articles are subject to peer review.
官方網站http://dl.begellhouse.com/journals/3667c4ae6e8fd136.html
在線稿件提交http://submission.begellhouse.com/usr/login.html?prod_code=journals
開放訪問No
出版商Begell House Inc.
主題領域医学
出版國/地區UNITED STATES
發行頻率隔月刊行
創刊年1984
每年文章數17每年文章數趨勢
黃金OA百分比1.92%
Web of Science 四分位
2023-2024
WOS Quartile: Q2

CategoryEditionJIF QuartileJIF RankingJIF Percentage
PHARMACOLOGY & PHARMACYSCIEQ2136/354
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0743-4863%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: >12 Week(s), or Invited contributions
競爭力 *來自作者的數據: Moderate
參考鏈接
相關期刊 【CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    PHARMACOLOGICAL REVIEWSH-index: 210

    CiteScore: 34.70
    DRUG RESISTANCE UPDATESH-index: 100

    CiteScore: 26.20
    ADVANCED DRUG DELIVERY REVIEWSH-index: 278

    CiteScore: 28.10
    TRENDS IN PHARMACOLOGICAL SCIENCESH-index: 201

    CiteScore: 23.90
    PHARMACOLOGY & THERAPEUTICSH-index: 180

    CiteScore: 23.00
    MEDICINAL RESEARCH REVIEWSH-index: 119

    CiteScore: 29.30
    PHARMACOLOGICAL RESEARCHH-index: 118

    CiteScore: 18.70
    ARCHIVES OF PHARMACAL RESEARCHH-index: 75

    CiteScore: 13.40
    BIOMEDICINE & PHARMACOTHERAPYH-index: 78

    CiteScore: 11.90
    BRITISH JOURNAL OF PHARMACOLOGYH-index: 190

    CiteScore: 15.40
    學科內最受檢索的期刊 頁面查看次數
    BIOMEDICINE & PHARMACOTHERAPY498358
    PHYTOMEDICINE340412
    LIFE SCIENCES285930
    International Journal of Pharmaceutics242454
    PHARMACOLOGICAL RESEARCH241396
    European Journal of Pharmacology204266
    BIOCHEMICAL PHARMACOLOGY202709
    JOURNAL OF NATURAL PRODUCTS196705
    BRITISH JOURNAL OF PHARMACOLOGY165164
    MOLECULAR PHARMACEUTICS162841
  •  

    CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS] 的評論撰寫評論
作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 20:11:57 評論於
The discussion section is the core part of an SCI paper because it can reflect the breadth and depth of the author's research. Therefore, there is no specified word limit for this section. The length of the discussion section varies depending on the article and the author, with some being several thousand words long and others being tens of thousands of words long
(0) 讚! | 维尔娜菲茨杰拉德

作者: 维尔娜菲茨杰拉德


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-30 15:54:44 評論於
The discussion section is the core part of an SCI paper, as it reflects the breadth and depth of the author's research. Therefore, there is no specific word limit for this section. Depending on the article and the author, the length of the discussion section varies, from a few thousand words to tens of thousands of words
(0) 讚! | 维尔娜菲茨杰拉德

作者: 破戒阳平


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-27 23:47:21 評論於
Is the lengthy discussion showcasing the author's reflection on the topic? Does the reviewer have a positive impression of the manuscript?
(0) 讚! | 破戒阳平

作者: 魂魄彦露


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2021-12-26 14:16:34 評論於
How many words should be included in a typical discussion?
(0) 讚! | 魂魄彦露

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2017-07-16 21:28:50 評論於
Made a fortune! Published an article last year, and this year it broke 6 points. Dear friends, you also need to have such vision
(0) 讚! | 凌霄高洁

作者: 凌霄高洁


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2012-11-28 15:24:19 評論於
Can we reach the 3-point line next year? Let's discuss
(0) 讚! | 凌霄高洁

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [CRITICAL REVIEWS IN THERAPEUTIC DRUG CARRIER SYSTEMS] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*